The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Given the significance of antibiotic resistant bacteria it is possible the process might be quicker if governments want it fast tracked. We shall have to wait and see!.
3 new positions
RNSS says first patient dosed in phase 3 trial for Ridinilazole. Going to take two and half years for the full data so patience as well as patients required, but there's every reason to hope this will do the job. I hope something else in our pipeline will come forward to keep the interest levels up - gonorrhea drug sounds promising and necessary.
Summit Therapeutics to begin Phase 3 studies of ridinilazol this quarter:
http://www.proactiveinvestors.co.uk/companies/stocktube/12162/summit-therapeutics-to-begin-phase-3-studies-of-ridinilazol-this-quarter-12162.html
thanks, i did do that but struggled to tie up the dates. i hope they recover, i am interested so will have a read up.
Because we discovered our DMD drug did not work. You can find out more by looking at the RNS feed for the time.
Hi All
can anyone tell me why the sudden drop in SP last June 18.
thanks
From where the Nasdaq excitement left off Friday
As you say even as a PR exercise buying SUMM an easy win for Big Pharma. Clearly better science news will help but i am content to hold.
Summit Therapeutics (SMMT) Receives a Hold from Oppenheimer
https://www.smarteranalyst.com/brief/summit-therapeutics-smmt-receives-a-hold-from-oppenheimer/
Good to see the growing media attention around the need for new, narrow spectrum, antibiotics. Destiny Pharmas SP seems to be benefiting (unfortunately I don't hold any). Hopefully SUMM can market themselves a little better and attract some media attention too..Investment will come once there's a clearer way forward on how the health authorities/governments will pay for the end product. I think that came across in last night's program and made it very clear that we're up a certain creek without a paddle unless we increase investment now and make changes to the way we pay for them... SUMM does seem like an attractive buying opportunity for any big pharma wishing to get into, or expand, their presence in the antibiotic arena (even as a PR exercise, given the growing media attention).. Just a matter of patience - unfortunately no pill for that!
Per waterloo01 from the other board:
BBC programme tonight on antibiotics (another one) and US live streaming now and tomorrow, presidential committee on combating antimicrobial resistance
https://www.hhs.gov/live/live-1/index.html#9902
What we need is a change in sentiment toward investment in antibiotics.
There is much government and political pressure on Big Pharma to develop new antibiotics. How much would it cost to buy a controlling interest in SUMM this week? £20 million? The market cap is only £37 mn so not much when one considers the size of AZNs annual Research and Development Budget......
Thanks Chris appreciated. These are one of the most unloved and undervalued stocks I know at present and like UPGS I was heavily buying in and lowering average at 32p. That has paid off now and these will really pay of in Q1/Q2 2019. Average here 31p and expecting 100% profit minimum shortly! Good luck all
Hi stew200 - The next planned news will be the announcing of the start of Phase 3 for C-Diff this quarter & the next news will be the release of the Full Year accounts 31.01.19 late this quarter or early next.All a bit quite but I am expecting that there will have been some improvement in the SP by the end of Qtr 2 also no-one pumps the amount of money the recent new shareholder has done if there will be no expected improvement this year.
Why this price hasn’t moved much higher with so much to look forward to
Very good news!
UK government to pump millions into antibiotics research for superbug fight (Good article):
https://www.proactiveinvestors.co.uk/companies/news/213280/
Summit to participate in Bio CEO Investor Conference:
February 11 - 12, 2019 | New York, New York
https://www.bio.org/events/bio-ceo-investor-conference/companies
The interview with Matt Hancock on Peston last night was worth watching. Although Peston wanted to talk about Brexit Hancock made it very clear he was in Davos primarily to talk with world leaders about the growing/global need for new antimicrobials, to tackle resistance, and he wanted to talk about that.
I thought Hancock did more for SUMM than Glynn's interview the other day on proactive. Bit flat and he would have been better hammering home the message about the changing attitude of Governments and Health Authorities for reimbursing new/innovative antibiotics. Some links below on Scott Gottlieb from the FDA..
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm610503.htm
https://www.modernhealthcare.com/article/20180914/NEWS/180919913
The reality is reimbursement will have to change, and I'm personally invested here because I believe it will. Health Authorities know they will have to demonstrate to industry they are open for business, when it comes to antibiotics, and I'm sure we'll see more incentives during the time SUMM progress their Abx program through their pivotal trials..
Hi All - This mornings news as shown by waterloo01 & football must surely be good news for Summit which may slowly creep into the current SP.Its taken the Government some time to recognise the antibiotic resistance problem but good that it now has. Edit: Looks like someone has already seen the potential benefits to Summit this morning.
Posting per waterloo01 from the other board:
https://www.bbc.co.uk/news/health-46973641
The drugs advisory body, the National Institute for Health and Clinical Excellence, and NHS England will also trial a new payment model that means pharmaceutical companies will be paid for drugs based on how valuable the medicines are to the NHS, rather than by the quantity of drugs sold.
Per football from the other board:
Drug firms get millions for war on superbugs
First new class of antibiotics in four decades
https://www.thetimes.co.uk/edition/news/drug-firms-get-millions-for-war-on-superbugs-mm0lkr6p5
Hi Folks - I am looking at the NASDAQ which is currently 8.45% down to $1.30 = £0.20p & for me the longer it takes for the SP to improve gives me more time to find funds in order to Buy more shares so to average down.However will this share ever recover for me it needs to get to £1.00 5x where we are now?
Doctors need to double the dose of antibiotics they give to patients with gonorrhoea because it's becoming resistant to medicine, experts have warned.
The British Association for Sexual Health and HIV (BASHH) today issued new guidelines for treating the STI for the first time since 2011.
Its recommendations follow news released earlier this month that two women in the UK caught 'super gonorrhoea' - one of whom was the first to ever catch it in Britain.
BASHH urges doctors to stop using one of the routine antibiotics and to increase the dose of another in what it called 'a major change'.